In 2011, type 2 diabetes affected 366 million people worldwide and this prevalence is estimated to increase to 552 million by 2030 (1) . Individuals with type 2 diabetes are at increased risk of major cardiovascular events, including ischemic heart disease, stroke and heart failure (2) . In a contemporary analysis of a United Kingdom primary care population, type 2 diabetes was associated with twice the risk of all-cause mortality and 3 times the risk of cardiovascular mortality relative to age and sex-matched controls (3) . Consequently, prevention of diabetes is critically important for reducing the burden of cardiovascular disease (CVD).
While hypertension has long been recognized as an independent risk factor for fatal and nonfatal vascular events (4) , the relationship between blood pressure (BP) and risk of new-onset diabetes is less clear. Elevated BP is associated with chronic inflammation (5) and endothelial dysfunction (6) , both of which appear to be mediators of diabetes risk (7, 8) . There is, therefore, a biological rationale to suspect that elevated BP may cause new-onset diabetes. However, among 30 cohort studies that have reported the association of blood pressure and diabetes, 12 concluded that no such association is apparent, while the others reported a considerably variable strength of association (Online Table 1 ). Moreover, even the largest previous cohorts have had limited power to investigate whether any observed positive association between BP and diabetes varied significantly by important patient features (9) .
A detailed understanding of BP as a potential risk factor for diabetes will help us better understand and communicate risks with patients and can lead to more targeted prevention and management. We therefore undertook both an analysis of 4.1 million individuals free from diabetes and CVD in a contemporary U.K. primary care population and a meta-analysis of existing prospective studies to reliably determine the association between BP and diabetes.
METHODS
We used prospectively collected records from the U.K. Clinical Practice Research Datalink (CPRD) to assemble a cohort of 4.1 million patients free from vascular disease and diabetes. An electronic health record system, covering approximately 9% of the U.K. population, CPRD has been validated for epidemiological research into a range of diagnoses (10, 11) . Patients were additionally linked to Hospital Episode Statistics (HES), a data compository containing details of all admissions, outpatient appointments, and emergency hospital attendances. HES also provides information on cause-specific mortality for fatal hospital events.
PARTICIPANTS, EXPOSURES, AND OUTCOMES.
Patients were eligible for inclusion if they had a BP measurement performed between January 1, 1990, and January 1, 2013, and were between 30 to 90 years (inclusive) old at the time of measurement. Additionally, patients needed to have their age recorded and be registered at a general practice for at least 1 year. To reduce measurement error to which single BP measurements are prone and to diminish the impact of short-term fluctuations in BP on observed associations, the initial measurement was transformed into "usual blood pressure" to adjust for regression dilution bias and the calculated usual BP was used as the exposure. All patients with pre-existing vascular disease (ischemic heart disease, cerebrovascular disease, heart failure, peripheral vascular disease, or renal disease) and diabetes (13) . The variance of each estimate approximates the variance in the underlying category.
Multiple imputation using chained equations was used to impute missing covariates; 5 imputations were generated.
Measurement error and short-term fluctuations in BP will bias any potential association of BP with an outcome of interest to the null (an effect termed regression dilution bias). As we were interested in the etiological association of BP with risk of new-onset diabetes, free of regression dilution bias, we used similar methods to the Emerging Risk Factors Collaboration to adjust for regression dilution bias (14) (15) (16) (17) . That is, we regressed serial BP measurements within the median follow-up on the baseline BP measurement, but used generalized estimating equations, rather than linear models, to account for multiple serial BP measurements among participants. Regression dilution ratios were calculated as the inverse of the coefficient relating the serial measurements to the baseline measurement. Regression dilution ratios of 2.1 for SBP and 2.5 for DBP were estimated. Continuous HRs for measured BP (i.e., per 20/10 mm Hg) were then multiplied by these ratios to estimate the association for usual BP. (19, 20) . Sixth, diagnosis of diabetes was defined as an explicit diagnosis of type 2 diabetes (that is, excluding individuals who were only diagnosed with unspecified diabetes or prescribed antidiabetic medicine without a concomitant diagnosis of type 2 diabetes).
META-ANALYSIS.
A systematic search strategy was designed and conducted by an experienced research librarian to identify previous studies of the association between BP and risk of new-onset diabetes. The strategy included MeSH terms and synonyms for the terms blood pressure, incident, and diabetes. MEDLINE was searched from 1966 to January 2015, with no language restrictions applied. Prospective observational studies, including observational analyses of randomized trials, were eligible for inclusion if they: 1) had at least 1 year of follow-up; 2) reported a risk per unit of SBP that could be standardized to 20 mm Hg higher SBP; and 3) adjusted for, at minimum, sex, age, and BMI. The latter was required for adjustment given that BMI is a strong risk factor for diabetes (21) and is associated with elevated BP (22) . Studies conducted in populations immediately after renal transplantation and studies that examined gestational diabetes were excluded. Measures of relative risks (e.g., HRs and odds ratios [ORs]), difference in BP, study population, number of incident diabetes events, and degree of adjustment were extracted in duplicate. As no study adjusted for regression dilution bias, we pooled relative risks standardized to 20 mm Hg higher usual SBP by multiplying the reported relative risks per 20 mm Hg higher measured SBP by our regression dilution coefficient. Random effects metaanalysis was used due to the presence of high heterogeneity (I 2 >50%). Test for interaction between subgroups was performed using Cochran's Q test.
One study reported a relative risk of new-onset diabetes per 10 mm Hg higher DBP; this was assumed to correspond to a relative risk per 20 mm Hg higher SBP. Five studies reported relative risks of new diabetes comparing one-fifth of BP relative to another fifth but did not explicitly report a difference in SBP between fifths (9, 21, (23) (24) (25) . A normal approximation was therefore assumed to determine the approximate difference in BP between fifths to allow for standardization per 20 mm Hg higher SBP. These 5 studies were excluded in a sensitivity analysis.
Analyses were performed using R version 3.0. When all individuals prescribed blood pressure-lowering drugs or statins at baseline or during follow-up were excluded in a sensitivity analysis, estimates were similar (Online Figure   2 ). Further adjustment for total and HDL cholesterol, socioeconomic status, and period of initial BP measurement also had little effect on estimated associations between SBP and DBP and risk of new-onset diabetes (Online Figures 3 and 4) . Exclusion of individuals diagnosed with diabetes within the first 2 years and within the first 4 years of follow-up also had little effect on associations (Online Figures 5 and 6 ). Estimates also did not change materially when diabetes was restricted to explicit diagnosis of type 2 diabetes (Online Figure 7) .
RESULTS

META-ANALYSIS.
Thirty prospective observational studies were identified (Online Figure   8) Figure   4 ). A test for interaction with our estimate of 58% higher risk of diabetes per 20 mm Hg usual SBP was not significant (p = 0.14). The overall pooled coefficient, including our and previous cohort studies, was 76% per 20 mm Hg higher usual SBP (RR: 1.76; 95% CI: 1.56 to 1.97).
Estimates were similar when 5 studies that used a normal approximation to determine the BP difference associated with the provided relative risk were excluded (Online Figure 9 ).
DISCUSSION
In a cohort of people without known prior vascular disease and with more than 180,000 (27) . However, in a prospective cohort study of risk factors for diabetes in 7,097 men, no association was observed between baseline BP and diabetes risk after adjustment for clinical and demographic covariates (21) . These qualitatively and quantitatively discrepant findings are most likely due to the limited power of individual studies to reliably measure modest risk associations, as supported by our systematic review, which shows that the pooled estimate across these studies support a modest association between elevated SBP and risk of diabetes (Figure 4) . (20) , suggesting it is renin-angiotensin system (RAS) activation that is causally related to risk of new-onset diabetes and not BP per se. However, the lack of a reduction in new diabetes observed for diuretics, beta-blockers, and calcium channel blockers may be due to off target effects for these therapies rather than a lack of a relationship between BP and diabetes risk (29) .
Previous analyses have suggested that a causal relationship between mediators of chronic inflammation, specifically interleukin-6, and incident diabetes may exist (7, 30) . Chronic inflammation characterizes both obesity (31) and elevated BP (5), risk factors for diabetes, and is reduced by RAS inhibition (32) . Thus, chronic inflammation may mediate, in part, the relationship between both risk factors (obesity and hypertension) and incident diabetes.
Alternatively, endothelial dysfunction may link elevated BP and diabetes (8) . An individual patient data meta-analysis, such as the Blood Pressure Lowering Treatment Trialists' Collaboration, would be ideally suited to examine whether BP lowering, independent of RAS inhibition, reduces the risk of new diabetes.
Assuming causality, this analysis suggests that individual-and population-based efforts to lower BP may as well lower the incidence of diabetes. As RAS inhibition has been demonstrated to reduce the incidence of new diabetes in randomized trials, prescription of ACE inhibitors and ARBs has the most reliable evidence base for reducing the incidence of diabetes at an individual level. Although we observed a declining proportional association between BP and risk of diabetes with increasing BMI, the greater absolute risk of diabetes at higher BMI would support targeting individuals with high BMI for BP lowering to prevent diabetes. Populationbased efforts to lower BP, for example, by reducing alcohol consumption through policy implementation or by promoting exercise, may also lead to reductions in the incidence of diabetes. However, further research is needed to examine the causality of the described associations and determine whether BP lowering without renin-angiotensin inhibition would reduce risk of new-onset diabetes.
STUDY LIMITATIONS.
This analysis has several strengths, including its large size, encompassing more than 4.1 million individuals and 180,000 incident diabetes events, and contemporary nature. One potential limitation is that we utilized routinely collected electronic health records for our analysis. Although this approach has recently been used to examine the relationship between type 2 diabetes and cardiovascular risk, it is possible that some of our type 2 diabetes events may have been misclassified (e.g., metabolic syndrome but not type 2 diabetes). However, a previous study suggested that physician-diagnosed type 2 diabetes events in CPRD are highly reliable (33) . Furthermore, we supplemented our analysis with a metaanalysis of prospective observational studies within 285,664 individuals and 17,388 incident diabetes events. This complementary approach increased our study's reliability, allowing us to first validate our estimate against previous studies and then examine the relationship between BP and risk of diabetes in various subpopulations. Our estimate of an overall 58% increase per 20 mm Hg higher usual SBP was consistent with our meta-analysis of previous observational studies that largely used adjudicated diabetes events and was consistent in 6 sensitivity analyses, including an analysis of explicit diagnoses of type 2 diabetes (rather than unspecified diabetes).
CONCLUSIONS
A 20 mm Hg higher SBP was associated with a 58% higher risk of new-onset diabetes, while a 10 mmHg higher DBP was associated with a 52% higher risk of developing diabetes. The strength of the association declined with increasing BMI and age. Further investigation is needed to determine whether this association is causal.
Perspectives
Competency in Medical Knowledge: Elevated blood pressure is associated with the risk of developing diabetes, and there is no nadir in the normotensive range.
Translational Outlook: Randomized trials are needed to establish causation and to determine whether lowering blood pressure, particularly by administration of inhibitors of the reninangiotensin-aldosterone system, will reduce the risk of developing diabetes. simultaneously. Floating absolute risks were used to display all hazard ratios (13) . The variance of each estimate approximates the variance in the underlying category.
FIGURE 2 Adjusted HR for Diabetes by SBP and BMI or Age
Adjustments were for smoking status, sex, and the interaction between SBP as a categorical variable and (A) BMI category (plotted) and (B) age category (plotted). Abbreviations as in Figure 1 .
FIGURE 3 Association between BP and Diabetes per Baseline Variables
Adjustments were for age, sex, BMI, baseline antihypertensive use, and baseline lipid-lowering therapy use. For subgroups of age, adjustment was also for age category and the interaction between SBP and age category (plotted). For subgroups of sex, adjustment was also for the interaction between sex and SBP (plotted). For subgroups of BMI, adjustments were also for BMI category and the interaction between SBP and BMI category (plotted). Area of each square is proportional to the inverse variance of the estimate. In various subgroups (usual SBP or DBP, sex, BMI, and age), proportional associations were seen between newly diagnosed diabetes and a 20 mm Hg higher SBP or 10 mm Hg higher DBP. A greater proportional risk was seen with the lowest BMI category versus the highest in both BP groups; similarly, increasing age was associated with decreasing risk. Abbreviations as in Figure 1 .
FIGURE 4 Association between Higher Usual SBP and Diabetes Risk
A meta-analysis showed that each 20 mm Hg higher usual SBP from prior cohort studies was associated with a 77% higher risk of new diabetes. Study refers to first author of study.
Abbreviations as in Figure 1 . 
